Dyslipidemia plays an essential role in the occurrence and development of cardiovascular diseases, and the regulation of cholesterol and triglyceride metabolism has been applied in the diagnosis, treatment and prognosis of clinical cardiovascular diseases. Following advances in methodology in recent years, low-density lipoprotein triglycerides (LDL-TG) has been identified as a potential risk factor for the development of cardiovascular disease and has some clinical significance in its diagnosis and treatment. Meanwhile, LDL-TG metabolism regulation may also be involved in the development of type 2 diabetes, chronic kidney disease, hypothyroidism and other diseases, which may improve our understanding of the prevention, control and risk assessment of clinically relevant diseases.
{"title":"Low-density lipoprotein triglycerides: A marker for metabolic diseases.","authors":"Xiangxiang Li, Hao Shen","doi":"10.1684/abc.2023.1840","DOIUrl":"10.1684/abc.2023.1840","url":null,"abstract":"<p><p>Dyslipidemia plays an essential role in the occurrence and development of cardiovascular diseases, and the regulation of cholesterol and triglyceride metabolism has been applied in the diagnosis, treatment and prognosis of clinical cardiovascular diseases. Following advances in methodology in recent years, low-density lipoprotein triglycerides (LDL-TG) has been identified as a potential risk factor for the development of cardiovascular disease and has some clinical significance in its diagnosis and treatment. Meanwhile, LDL-TG metabolism regulation may also be involved in the development of type 2 diabetes, chronic kidney disease, hypothyroidism and other diseases, which may improve our understanding of the prevention, control and risk assessment of clinically relevant diseases.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":"475-482"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
François Grand, Florence Blanc-Jouvan, Céline Delassasseigne, Hubert Galinat, Pierre-Marie Roy, Laurie Talon, Marie Toussaint-Hacquard, Laurent Macchi
Point-of-care testing (POCT) for D-dimer is an alternative to -laboratory testing for the exclusion of venous thromboembolism (VTE). This critical review by the "CEC et biologie délocalisée" working group of the "Société Française de Thrombose et d'Hémostase" (French Society of -Thrombosis and Haemostasis) aims to present the characteristics of six POCT D-dimer assays available in France in 2023. The article highlights the need to define VTE -exclusion thresholds specific to each technique and validated by clinical studies. There is insufficient data to validate the use of cut off suggested by manufacturers, and age-adjusted thresholds. The article discusses the role of laboratories in justifying and prescribing POCT D-dimer, according to objective criteria, such as the availability and turnaround time of classical laboratory tests. They should also encourage rational prescribing, limited to patients with low risk of venous thromboembolism, following an assessment of clinical probability according to national and international guidelines.
d -二聚体的即时检测(POCT)是实验室检测排除静脉血栓栓塞(VTE)的替代方法。法国血栓和止血学会的“CEC et biologie dsamlocalissame”工作组的这篇重要综述旨在介绍2023年法国可用的六种POCT d -二聚体测定方法的特点。这篇文章强调了确定静脉血栓栓塞排除阈值的必要性,具体到每一种技术,并通过临床研究验证。没有足够的数据来验证制造商建议的截断和年龄调整阈值的使用。本文根据客观标准,如经典实验室测试的可用性和周转时间,讨论了实验室在证明和处方POCT d -二聚体方面的作用。他们还应鼓励合理的处方,仅限于静脉血栓栓塞风险低的患者,并根据国家和国际指南对临床可能性进行评估。
{"title":"[Point-of-care testing for D-dimer in the exclusion of venous thromboembolism: a critical analysis].","authors":"François Grand, Florence Blanc-Jouvan, Céline Delassasseigne, Hubert Galinat, Pierre-Marie Roy, Laurie Talon, Marie Toussaint-Hacquard, Laurent Macchi","doi":"10.1684/abc.2023.1839","DOIUrl":"https://doi.org/10.1684/abc.2023.1839","url":null,"abstract":"<p><p>Point-of-care testing (POCT) for D-dimer is an alternative to -laboratory testing for the exclusion of venous thromboembolism (VTE). This critical review by the \"CEC et biologie délocalisée\" working group of the \"Société Française de Thrombose et d'Hémostase\" (French Society of -Thrombosis and Haemostasis) aims to present the characteristics of six POCT D-dimer assays available in France in 2023. The article highlights the need to define VTE -exclusion thresholds specific to each technique and validated by clinical studies. There is insufficient data to validate the use of cut off suggested by manufacturers, and age-adjusted thresholds. The article discusses the role of laboratories in justifying and prescribing POCT D-dimer, according to objective criteria, such as the availability and turnaround time of classical laboratory tests. They should also encourage rational prescribing, limited to patients with low risk of venous thromboembolism, following an assessment of clinical probability according to national and international guidelines.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[François Rousselet (1929-2023) and Jean-Pierre Bali (1941-2023)].","authors":"Jean-Louis Beaudeux, Alain Legrand","doi":"10.1684/abc.2023.1842","DOIUrl":"https://doi.org/10.1684/abc.2023.1842","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Romain Ravel-Chapuis, Léo Mottin, Maïssa Souissi, Agnès Lahary, Victor Bobée
The discovery of hemolytic anemia requires a meticulous investigation to determine its etiology. Among patients of African origin, it is not uncommon to find multiple constitutional red blood cell abnormalities, which can complicate diagnosis. We herein describe the case of a two-year-old child presenting with acute hemolytic anemia. A G6PD deficiency, hereditary spherocytosis, and a sickle cell trait A/S were simultaneously identified, all within the context of a primary infection with Parvovirus B19. This virus commonly triggers acute anemia in children exhibiting constitutional red blood cell abnormalities and need to be considered in such cases.
{"title":"[Hemolytic anemia in a two-year-old child: A case of multiple red blood cell abnormalities].","authors":"Romain Ravel-Chapuis, Léo Mottin, Maïssa Souissi, Agnès Lahary, Victor Bobée","doi":"10.1684/abc.2023.1843","DOIUrl":"https://doi.org/10.1684/abc.2023.1843","url":null,"abstract":"<p><p>The discovery of hemolytic anemia requires a meticulous investigation to determine its etiology. Among patients of African origin, it is not uncommon to find multiple constitutional red blood cell abnormalities, which can complicate diagnosis. We herein describe the case of a two-year-old child presenting with acute hemolytic anemia. A G6PD deficiency, hereditary spherocytosis, and a sickle cell trait A/S were simultaneously identified, all within the context of a primary infection with Parvovirus B19. This virus commonly triggers acute anemia in children exhibiting constitutional red blood cell abnormalities and need to be considered in such cases.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The proinsulin molecule results from the cleavage of pre-pro-insulin, produced in pancreatic beta cells. Its subsequent -cleavage allows the release of insulin, the key hormone of glycemia regulation and C-peptide in equimolar proportions. During fasting trial, insulinoma diagnosis relies on inadequately high insulin and C-peptide serum levels concomitant with an hypoglycemia. In this context, proinsulin assay can be interesting in the cases of discrepancy between the two parameters. In diabetes, endoplasmic reticulum stress and beta cells inflammation, lead to the secretion of misfolded proinsulin molecules. Thus, in type 2 diabetes, proinsulin/insulin ratio increases with the degree of insulin resistance. In type 1 diabetes, proinsulin/C-peptide ratio could predict the onset of diabetes in relatives. In our practice, serum pro-insulin determined using an Elisa immunoassay (Millipore®) during fasting trial can be complementary to C-peptide and insulin assays in relation to glycemia to label an hypoglycemia. In case of glucose intolerance and diabetes, proinsulin could thus be measured.
{"title":"[Proinsulin: physiology, measurement, and interest in clinical biology].","authors":"Katia Carvalho Alves, Fidéline Bonnet-Serrano, Christelle Laguillier, Vanessa Akiki, Léa Dehghani, Étienne Larger, Marie-Clémence Leguy, Jean Guibourdenche","doi":"10.1684/abc.2023.1838","DOIUrl":"https://doi.org/10.1684/abc.2023.1838","url":null,"abstract":"<p><p>The proinsulin molecule results from the cleavage of pre-pro-insulin, produced in pancreatic beta cells. Its subsequent -cleavage allows the release of insulin, the key hormone of glycemia regulation and C-peptide in equimolar proportions. During fasting trial, insulinoma diagnosis relies on inadequately high insulin and C-peptide serum levels concomitant with an hypoglycemia. In this context, proinsulin assay can be interesting in the cases of discrepancy between the two parameters. In diabetes, endoplasmic reticulum stress and beta cells inflammation, lead to the secretion of misfolded proinsulin molecules. Thus, in type 2 diabetes, proinsulin/insulin ratio increases with the degree of insulin resistance. In type 1 diabetes, proinsulin/C-peptide ratio could predict the onset of diabetes in relatives. In our practice, serum pro-insulin determined using an Elisa immunoassay (Millipore®) during fasting trial can be complementary to C-peptide and insulin assays in relation to glycemia to label an hypoglycemia. In case of glucose intolerance and diabetes, proinsulin could thus be measured.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marie-Hélène Tournoys, Marie-Christine Beauvieux, Valéry Brunel, Nicolas Collet, Samuel Cutullic, Yohan Darrieux, Tarik Es Sadki, Valentin Faivre, Pierre Yves Guyot, Mathilde Iberti, Felipe Le Divenah, Charles René Lefèvre, Nathalie Terrier, Jérôme Grosjean, Carole Poupon
{"title":"[Reports of the Match 180 seconds from the French-speaking Days of Medical Biology].","authors":"Marie-Hélène Tournoys, Marie-Christine Beauvieux, Valéry Brunel, Nicolas Collet, Samuel Cutullic, Yohan Darrieux, Tarik Es Sadki, Valentin Faivre, Pierre Yves Guyot, Mathilde Iberti, Felipe Le Divenah, Charles René Lefèvre, Nathalie Terrier, Jérôme Grosjean, Carole Poupon","doi":"10.1684/abc.2023.1846","DOIUrl":"10.1684/abc.2023.1846","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guillaume Grzych, Damien Gruson, Joe El Khoury, Bernard Gouget
{"title":"[The ADLM Annual Meeting 2023 at a glance!]","authors":"Guillaume Grzych, Damien Gruson, Joe El Khoury, Bernard Gouget","doi":"10.1684/abc.2023.1845","DOIUrl":"10.1684/abc.2023.1845","url":null,"abstract":"","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":"553-555"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The detection of erythrocyte morphological abnormalities is a valuable and sometimes overlooked element in the diagnostic management of anemias. The aim of this article is to evaluate the clinical performance of the different detection thresholds tested by our laboratory using the Cellavision RBC Advanced module, after manual reclassification by an experienced operator, and comparing them to the guidelines by the ICSH (International Council for Standardization in Haematology). We arbitrarily set thresholds at 1% for "critical" abnormalities (tear drop cells, target cells, schizocytes and spherocytes) except for sickle cells (threshold set at 0.01%). Our data show excellent sensitivity of 100% for the cut-offs defined by the investigation for tear drop cells and sickle cells, but low specificity for detection of associated clinical pathology compared with ICSH cut-offs, varying from 4% for teardrop cells (detection of myelofibrosis), 26% for target cells (detection of martial deficiency) to 55% for schizyocytes (presence of hemolytic anemia). Our results show a better specificity of the thresholds established by ICSH than our studied thresholds for the detection of the pathologies of concern, suggesting a better clinical relevance.
{"title":"[Evaluation of blood cell morphology with the RBC Advanced Application: Which cut-offs are most needed for which specific abnormalities?]","authors":"Rhita Bennis, Francois Mullier, Pascale Saussoy","doi":"10.1684/abc.2023.1837","DOIUrl":"https://doi.org/10.1684/abc.2023.1837","url":null,"abstract":"<p><p>The detection of erythrocyte morphological abnormalities is a valuable and sometimes overlooked element in the diagnostic management of anemias. The aim of this article is to evaluate the clinical performance of the different detection thresholds tested by our laboratory using the Cellavision RBC Advanced module, after manual reclassification by an experienced operator, and comparing them to the guidelines by the ICSH (International Council for Standardization in Haematology). We arbitrarily set thresholds at 1% for \"critical\" abnormalities (tear drop cells, target cells, schizocytes and spherocytes) except for sickle cells (threshold set at 0.01%). Our data show excellent sensitivity of 100% for the cut-offs defined by the investigation for tear drop cells and sickle cells, but low specificity for detection of associated clinical pathology compared with ICSH cut-offs, varying from 4% for teardrop cells (detection of myelofibrosis), 26% for target cells (detection of martial deficiency) to 55% for schizyocytes (presence of hemolytic anemia). Our results show a better specificity of the thresholds established by ICSH than our studied thresholds for the detection of the pathologies of concern, suggesting a better clinical relevance.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"81 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138453292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nassim Boutouchent, Maïssa Souissi, Gérard Buchonnet, Muriel Quillard, Victor Bobée
Iron deficiency is the leading cause of anemia worldwide, affecting approximately 600 million individuals. Once established, it typically manifests as a hypochromic microcytic anemia, the severity of which varies depending on the degree of deficiency. This anemia is frequently associated with thrombocytosis, but the presence of associated thrombocytopenia is much rarer. Here, we report a case of severe iron deficiency with an atypical presentation of bicytopenia, involving both severe anemia and profound thrombocytopenia, which rapidly resolved following iron supplementation. We then discuss the hypotheses that exist to explain the link between iron deficiency and regulation of thrombopoiesis.
{"title":"[Severe thrombopenia with iron deficiency anemia: about a case and literature review].","authors":"Nassim Boutouchent, Maïssa Souissi, Gérard Buchonnet, Muriel Quillard, Victor Bobée","doi":"10.1684/abc.2023.1833","DOIUrl":"https://doi.org/10.1684/abc.2023.1833","url":null,"abstract":"<p><p>Iron deficiency is the leading cause of anemia worldwide, affecting approximately 600 million individuals. Once established, it typically manifests as a hypochromic microcytic anemia, the severity of which varies depending on the degree of deficiency. This anemia is frequently associated with thrombocytosis, but the presence of associated thrombocytopenia is much rarer. Here, we report a case of severe iron deficiency with an atypical presentation of bicytopenia, involving both severe anemia and profound thrombocytopenia, which rapidly resolved following iron supplementation. We then discuss the hypotheses that exist to explain the link between iron deficiency and regulation of thrombopoiesis.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"0 0","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Inflammatory biological parameters are altered in patients with COVID-19 depending on its severity. The objective of our study is to find a score to assess the prognosis of patients with severe COVID-19. This is a retrospective study of patients with severe COVID-19 hospitalized in the intensive care units of Ibn Sina Hospital in Rabat. The study involves a total of 197 patients. The biological parameters were collected and evaluated in order to recognize the factors of poor prognosis of severe COVID-19. In our cohort, 133 patients died (67.51%) and had a higher average age (p < 0.001). A statistically significant correlation was found in this group of patients for procalcitonin (p = 0.005), lactate dehydrogenase (p = 0.02) and ferritin (p = 0.017). The lactate dehydrogenase/lymphocyte ratio (LLR) had the highest accuracy among the calculated combined scores. The LLR AUC was 0.628 (95% CI: 0.549-0.708) and the optimal cut-off value was 341, which gave a sensitivity of 91 % and a specificity of 84 %. The LLR is a good predictor of the poor prognosis of patients with severe COVID-19.
{"title":"[The lactate dehydrogenase to lymphocyte ratio in evaluating the prognosis of patients with severe COVID-19].","authors":"Redouane Mammar Bennai, Mounya Boudbellah, Nada Benabdelouahab, Badr-Eddine El Amri, Laila Benchekroun","doi":"10.1684/abc.2023.1836","DOIUrl":"https://doi.org/10.1684/abc.2023.1836","url":null,"abstract":"<p><p>Inflammatory biological parameters are altered in patients with COVID-19 depending on its severity. The objective of our study is to find a score to assess the prognosis of patients with severe COVID-19. This is a retrospective study of patients with severe COVID-19 hospitalized in the intensive care units of Ibn Sina Hospital in Rabat. The study involves a total of 197 patients. The biological parameters were collected and evaluated in order to recognize the factors of poor prognosis of severe COVID-19. In our cohort, 133 patients died (67.51%) and had a higher average age (p < 0.001). A statistically significant correlation was found in this group of patients for procalcitonin (p = 0.005), lactate dehydrogenase (p = 0.02) and ferritin (p = 0.017). The lactate dehydrogenase/lymphocyte ratio (LLR) had the highest accuracy among the calculated combined scores. The LLR AUC was 0.628 (95% CI: 0.549-0.708) and the optimal cut-off value was 341, which gave a sensitivity of 91 % and a specificity of 84 %. The LLR is a good predictor of the poor prognosis of patients with severe COVID-19.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"0 0","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138178253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}